Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

DRD2 promoter region variation predicts antipsychotic-induced weight gain in first episode schizophrenia

21 Jul 2010

Abstract excerpt

Many antipsychotic medications carry a substantial liability for weight gain, and one mechanism common to all antipsychotics is binding to the dopamine D2 receptor. We therefore examined the relationship between -141C Ins/Del (rs1799732), a functional promoter region polymorphism in DRD2, and antipsychotic-induced weight gain in 58 first episode schizophrenia patients enrolled in a randomized trial of risperidone...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bipolar Disorder and Treatment
Share to Diabetes Treatment and Management

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Schizophrenia research and treatment

Source

Identifiers

PMID: 20664489
DOI: 10.1097/fpc.0b013e32833ca24b

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 22 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

DRD2 promoter region variation predicts antipsychotic-induced weight gain in first episode schizophreniaPMID 20664489Read ↗

Systematic analysis of dopamine receptor genes (DRD1-DRD5) in antipsychotic-induced weight gain.Semantic proximity Read ↗

Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia.Semantic proximity Read ↗

Role of 5-HT2C receptor gene variants in antipsychotic-induced weight gainSemantic proximity Read ↗

Dopamine receptor D2 gene is associated with weight gain in schizophrenic patients under long-term atypical antipsychotic treatment.Semantic proximity Read ↗

Pharmacogenetics of antipsychotic-induced weight gain: review and clinical implications.Semantic proximity Read ↗

A meta-analysis of potential genetic factors associated with antipsychotic-induced weight gain in adults with severe mental illness.Semantic proximity Read ↗

Antipsychotic induced weight gain: genetics, epigenetics, and biomarkers reviewed.Semantic proximity Read ↗

Genetics of antipsychotic treatment emergent weight gain in schizophrenia.Semantic proximity Read ↗

Genetics of antipsychotic-induced weight gain: update and current perspectives.Semantic proximity Read ↗

Genetic association of the rs17782313 polymorphism with antipsychotic-induced weight gain.Semantic proximity Read ↗

Association of antipsychotic drug-induced weight gain with a 5-HT2C receptor gene polymorphism.Semantic proximity Read ↗

Polymorphisms of the HTR2C gene and antipsychotic-induced weight gain: an update and meta-analysis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.